GlaxoSmithKline’s ViiV Healthcare has already shown that a two-drug HIV regimen can stand up with its three-drug competitors. But now it has data showing a pairing can do the same with dosing just once per month. More: Glaxo's ViiV touts
read moreAnalysts welcomed Roche’s $4.8 billion takeover of Spark Therapeutics because of Spark’s novel gene therapy platform and potential enhancements in hemophilia and eye disease. But the acquisition didn’t come easy. More: Roche fought through a bidding war to land its Spark
read moreSanofi’s dengue ambitions are all but dashed in the Philippines, but the company still hopes its Dengvaxia vaccine can deliver the goods elsewhere. Those hopes took another hit, though, with a lukewarm reception from the FDA’s expert advisers. More: Sanofi's Dengvaxia faces
read moreUS regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps. More: FDA grants Dupixent Priority Review for sinusitis Source: News
read moreNICE has published a draft updated guideline on the diagnosis and management of high blood pressure, with thousands more patients to qualify for treatment. More: NICE updates high blood pressure guidelines Source: News
read moreEuropean regulators have validated Merck’s application Bavencio for review in kidney cancer. More: EMA validates Bavencio for review in advanced RCC Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals